Ligand Pharma: Revolade Receives EU Approval To Treat Aplastic Anemia

(RTTNews) - Ligand Pharmaceuticals Incorporated (LGND) announced the European Commission has approved Revolade (eltrombopag), a Novartis product, for the treatment of adults with severe aplastic anemia who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplant. The approval is based on the results of a pivotal open-label Phase 2 study and two supporting Phase 2 studies.

In August of 2014, eltrombopag, marketed as Promacta in the U.S., was approved by the FDA for once-daily use in patients with severe aplastic anemia who have had an insufficient response to IST.